Please login to the form below

Not currently logged in
Email:
Password:

EMA drug communication reviewed

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report.

The report represents the outcome of a year-long project carried out by Dr Frederic Bouder, from Maatstricht University, on the invitation of the agency.

Dr Bouder carried out a detailed analysis of the expectations and attitudes of the agency's stakeholders towards its communication on medicines.

He recommended that the agency set up a risk communication advisory board, form a strategic view on transparency, involve patients in communication activities on a routine basis, and review the format and timing of its communication vehicles.

The EMA has started implementing some of Dr Bouder's suggestions. It is also considering his recommendations during the implementation of the new pharmacovigilance legislation.

The EMA has the report available to download (PDF).

1st June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...